This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune…
- Investigator
- Michael R Bubb
- Ages
- 18 Years - 75 Years
- Sexes
- All